RenovaCare Inc represents values of innovation, patient-centric care, and technological advancement in the field of regenerative medicine. The company's corporate philosophy is centered around providing cutting-edge solutions for patients with severe burns, wounds, and other skin-related conditions. RenovaCare Inc aims to revolutionize the traditional approach to wound healing by utilizing its patented CellMist System, which allows for the gentle and efficient harvesting of a patient's own skin cells for subsequent spray-on application. With a focus on improving patient outcomes and enhancing quality of life, RenovaCare Inc remains committed to developing novel therapies and setting new standards in the field of regenerative medicine.

RenovaCare Inc is primarily present in the United States.

RenovaCare Inc has achieved several significant milestones. One of the major achievements is the development of their innovative SkinGun technology, which allows for the spraying of a patient's own stem cells onto burn wounds, promoting faster healing and recovery. Additionally, the company successfully conducted multiple clinical trials, demonstrating the efficacy of their technology in treating burns and other skin injuries. RenovaCare Inc also received recognition and awards for their breakthrough innovations, including the Frost & Sullivan's Technology Innovation Leadership Award. These milestones highlight the company's dedication to revolutionizing skin regeneration and positioning them as a leader in the field.

RenovaCare Inc is a biotechnology company specializing in the development and commercialization of innovative medical devices for wound healing and tissue regeneration. Founded in 2004, RenovaCare focuses on utilizing its patented SkinGun™ technology to spray a patient's own regenerative cells on burn and wound injuries, promoting faster healing and reduced scarring. RenovaCare's mission is to improve the quality of life for patients and revolutionize the field of regenerative medicine. With a strong emphasis on research and development, RenovaCare is committed to advancing its technologies to address unmet medical needs and have a positive impact on the healthcare industry.

The main competitors of RenovaCare Inc in the market include Avita Medical Ltd, Misonix Inc, and PolarityTE Inc.

RenovaCare Inc is primarily active in the medical devices industry.

The business model of RenovaCare Inc involves developing medical-grade technologies that aim to address the limitations of current wound care methods. The company is focused on the research, development, and commercialization of its proprietary CellMist™ System. This patented technology is designed to use a patient's own skin cells to create a Spray-On Skin™ solution, which can be applied to wounds to facilitate faster and more effective healing. RenovaCare aims to provide a non-invasive, cost-effective, and painless solution for patients suffering from burns, chronic wounds, and other skin-related conditions, with the ultimate goal of improving quality of life for individuals in need of advanced wound care treatment.

ניתן לחשב את מכפיל הרווח למניה נוכחית לא RenovaCare.

נכון לעכשיו לא ניתן לחשב את ה-KUV עבור RenovaCare.

תוצאת איכות AlleAktien עבור RenovaCare היא 3/10.

לא ניתן לחשב כרגע את ההכנסה עבור RenovaCare.

לא ניתן לחשב כרגע את הרווח עבור RenovaCare.

RenovaCare Inc. is a biopharmaceutical company from the USA that specializes in the development and commercialization of innovative therapeutics and medical products. The company focuses particularly on the regeneration of human tissue. RenovaCare aims to revolutionize the regeneration of skin tissue by offering innovative and safe therapy options. One of RenovaCare's most important areas of focus is the development of innovative products for the treatment of severe skin injuries and wounds. In particular, autologous cell therapy is an important approach. The company uses a patented technology called "Spray-On Skin" to naturally regenerate skin tissue using the patient's own cells. Cells are obtained from a small skin sample of the patient and processed in a specialized procedure in a matter of hours. The cells are then applied to the affected areas of the skin using a spray device, where they grow into natural, healthy skin. RenovaCare also offers a special device called the SkinGun, which allows for quick and easy implementation of autologous cell therapy. The device is compact and user-friendly, which is particularly advantageous in emergency medicine. Another important focus area for RenovaCare is the development of innovative products for burn treatment. This includes the patented "Spray-On Burn Treatment," which enables the quick and simple treatment of burns. In this procedure as well, the patient's own cells are used to regenerate the affected tissue. Furthermore, RenovaCare has a team of highly qualified scientists and researchers who collaborate closely with leading universities and institutes to develop new and innovative solutions in the field of human tissue regeneration. Thanks to this collaboration, RenovaCare is able to continuously drive groundbreaking developments and bring new therapy options to the market. RenovaCare's business model is based on the development and commercialization of innovative therapeutics and medical products for human tissue regeneration. The company utilizes the use of autologous cells to enable natural regeneration. RenovaCare collaborates closely with leading scientists and researchers and has a team of highly skilled professionals to drive its innovations. Overall, RenovaCare is an innovative company specializing in the development of therapeutics and medical products for human tissue regeneration. Through high-quality research and development work, the company is able to continuously develop groundbreaking solutions and bring new therapy options to the market.

RenovaCare מחלקת דיבידנד בסכום של 0 USD במספר תשלומים במהלך השנה.

לא ניתן לחשב כרגע את הדיבידנד עבור RenovaCare או שהחברה אינה מפרישה דיבידנד.

ISIN של RenovaCare היא US75988J1060.

ה-WKN של RenovaCare הוא A1XB0J.

הטיקר של RenovaCare הוא RCAR.

במהלך 12 החודשים האחרונים, RenovaCare שילמה דיבידנד בגובה . זה מקביל לתשואת דיבידנד של כ-. ל-12 החודשים הקרובים, RenovaCare צפויה לשלם דיבידנד של 0 USD.

תשואת הדיבידנד של RenovaCare נוכחית היא .

RenovaCare משלמת דיבידנד רבעוני. הדיבידנד מתבצע בחודשים .

RenovaCare שילם דיבידנד כל שנה במשך ה-0 שנים האחרונות.

לתקופה הבאה של 12 חודשים ניתן לצפות לדיבידנדים בסך של 0 USD. זה מייצג תשואת דיבידנד של 0 %.

RenovaCare משויך למגזר 'בריאות'.

כדי לקבל את הדיבידנד האחרון של RenovaCare מתאריך 31.10.2024 בסך 0 USD, היה עליך להחזיק את המניה לפני היום המוקדם בתאריך 31.10.2024 בתיק.

תשלום הדיבידנד האחרון בוצע ב-31.10.2024.

בשנת 2023 שילמה RenovaCare 0 USD כדיבידנדים.

הדיבידנדים של RenovaCare מתחלקים ב-USD.